Spots Global Cancer Trial Database for Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
Official Title: A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Study ID: NCT01948180
Interventions
Study Description
Brief Summary: To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana-Farber Cancer Center, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Baylor College of Medicine, Houston, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Universitaire Ouest, Paris, , France
Centre Hospitalier de Lyon, Pierre Bénite, , France
Samsung Medical Center, Seoul, , Korea, Republic of
Asan Cancer Center, Seoul, , Korea, Republic of
University College London Hospital, London, UK, United Kingdom
The Christie Clinic, Manchester, UK, United Kingdom
Contact Details
Name: Helen Heslop, MD
Affiliation: Baylor College of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Kurt Gunter, MD
Affiliation: Cell Medica
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
